AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00534300
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 100 mL, 25mL/h
Trial: NCT03151772
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
Trial: NCT04102696
Drug: Aromatherapy
RxNorm normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL CLOTH [Roots Aromatherapy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.
Trial: NCT04102696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
Trial: NCT04135989
Drug: Standard DAPT duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of dual antiplatelet therapy for 12 months.
Trial: NCT01490086
Drug: RP5063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT01490086
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT03418805
Drug: Ibuprofen CR Tablets 600 mg
RxNorm normalized name: ibuprofen Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively
Trial: NCT02235272
Drug: XG-102
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Trial: NCT02235272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Trial: NCT04372979
Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
Trial: NCT04372979
Drug: Transfusion of standard Plasma.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
Trial: NCT00909883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT02182999
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Trial: NCT00498368
Drug: ACE/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
Trial: NCT03149991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo which matches brexpiprazole in size and number of tablets per dose
Trial: NCT00648726
Drug: cefuroxime plus erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
Trial: NCT00648726
Drug: azithromycin (Zithromax)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
Trial: NCT01224015
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Trial: NCT02092506
Drug: 10 day triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 day triple therapy
Trial: NCT02092506
Drug: 10 day sequential therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 day sequential therapy
Trial: NCT02092506
Drug: 10 day concomitant therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 day concomitant therapy
Trial: NCT01962909
Drug: PTP-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 is 10mCi (50ug of peptide)
Trial: NCT01895075
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline by inhalation
Trial: NCT00001832
Drug: gp100:209-217 (210M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
Trial: NCT01501162
Drug: hepatitis, alcohol, probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of probiotics (1500 mg/day)
Trial: NCT01501162
Drug: alcohol, hepatitis, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
Trial: NCT02108210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02853565
Drug: CAN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
Trial: NCT00001832
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2x30 mg/kg, 2x60 mg/kg intravenous
Trial: NCT01394055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo volume subcutaneously once
Trial: NCT00474773
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01785290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9%
Trial: NCT03220425
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01832480
Drug: MTZ 500 mg twice daily x 7 days
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTZ 500 mg twice daily x 7 days
Trial: NCT01832480
Drug: MTZ 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ 2 g
Trial: NCT02591836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00906828
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intestinal gel, continuous infusion (daytime or 24-hour)
Trial: NCT00092885
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00731185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01038011
Drug: drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00251576
Drug: A-Phase: tirofiban; Z-Phase simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00251576
Drug: Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00251576
Drug: Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00251576
Drug: Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00251576
Drug: Duration of Treatment: Z-Phase, 2 years.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04222686
Drug: Perindopril Arginine
RxNorm normalized name: Perindopril Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Trial: NCT00372294
Drug: Clindamycin+Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of Clindamycin+Dexamethasone
Trial: NCT00102804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration, q 21 days
Trial: NCT00704184
Drug: Comparator: Pegylated-Interferon (Peg-IFN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
Trial: NCT00704184
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to vaniprevir; duration of treatment: 28 days
Trial: NCT04412668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT03954704
Drug: mFOLFOX6 Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
Trial: NCT04137055
Drug: ZSP0678-10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablet administered orally under fasted condition
Trial: NCT01764464
Drug: Gralise®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
Trial: NCT01764464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
Trial: NCT04137055
Drug: ZSP0678-30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted condition
Trial: NCT04137055
Drug: ZSP0678-120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted condition
Trial: NCT04137055
Drug: ZSP0678-180mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted condition
Trial: NCT04137055
Drug: ZSP0678-240mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted condition
Trial: NCT04137055
Drug: ZSP0678-320mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted condition
Trial: NCT04137055
Drug: ZSP0678
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally under fasted or fed condition
Trial: NCT04137055
Drug: ZSP0678-Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally once daily for 14 Days
Trial: NCT04137055
Drug: ZSP0678-Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally once daily for 14 Days
Trial: NCT04137055
Drug: ZSP0678-Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP0678 tablets administered orally once daily for 14 Days
Trial: NCT04137055
Drug: ZSP0678 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP0678 orally.
Trial: NCT04019197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection
Trial: NCT03557229
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral: 50 mg once daily for 5 days
Trial: NCT03557229
Drug: Vitamin C 1 GM Oral Tablet
RxNorm normalized name: vitamin C 1 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral: 1 GM every 6 hours for 5 days
Trial: NCT00542425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous daily
Trial: NCT00542425
Drug: BA058 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA058 20 µg subcutaneous daily
Trial: NCT00542425
Drug: BA058 40 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA058 40 µg subcutaneous daily
Trial: NCT00542425
Drug: BA058 80 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA058 80 µg subcutaneous daily
Trial: NCT02578095
Drug: VK5211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT02578095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT02641847
Drug: doxorubicin or epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641847
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01735019
Drug: Administration of remifentanil with TCI system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
Trial: NCT01115959
Drug: placebo bid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02812394
Drug: Sinemet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
Trial: NCT03809312
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos BID x 10 days
Trial: NCT03194204
Drug: Doxycycline Tablets
RxNorm normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
Trial: NCT02344654
Drug: Urografin
RxNorm normalized name: Urografin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01546857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00809263
Drug: homeopathic remedy
RxNorm normalized name: Quality Choice Homeopathic Remedy Ear Relief Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic remedy 12C potency, 10 drops TID X 7 days
Trial: NCT00374127
Drug: Marijuana blunt
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
Trial: NCT00374127
Drug: marijuana cigarette
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana cigarettes were provided by the National Institute on Drug Abuse.
Trial: NCT01180465
Drug: LIPO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPO-102 High dose
Trial: NCT01180465
Drug: LIPO-102, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03348917
Drug: Plain non antibacterial soap
RxNorm normalized name: QSR Antibacterial Soap Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guardian gel hand wash (not medicated),
Trial: NCT01388491
Drug: desogestrel/ethinyl estradiol
RxNorm normalized name: DESOGESTREL/ETHINYL ESTRADIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast placebo-matching tablets
Trial: NCT02079844
Drug: Second generation antipsychotic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
Trial: NCT00073034
Drug: EAA-090
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00203411
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
Trial: NCT02299206
Drug: Desitin Maximum Strength Original Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
Trial: NCT03381352
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825mg/m2 PO BID
Trial: NCT01402375
Drug: Hydrocodone (first trial)
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
Trial: NCT01402375
Drug: Codeine (first trial)
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Trial: NCT01402375
Drug: Codeine (for second trial)
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
Trial: NCT01402375
Drug: Hydrocodone (third trial)
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
Trial: NCT04973722
Drug: LY06006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/1 ml, once every 6 months administered subcutaneously
Trial: NCT02541565
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02541565
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01145404
Drug: Lapatinib plus capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
Trial: NCT01481714
Drug: Sodium picosulphate, magnesium oxid and citric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation
Trial: NCT01481714
Drug: Sodium picosulphate/magnesium oxide and citric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am.
Trial: NCT03128606
Drug: GLPG3067 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3067 oral suspension, single ascending doses, daily
Trial: NCT03128606
Drug: GLPG3067 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3067 oral suspension, single dose, daily
Trial: NCT01522898
Drug: Medical Ventricular Rate Control
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventricular Rate Control with target ventricular rate of 90 beats per minute.
Trial: NCT01911715
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03128606
Drug: GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
Trial: NCT02496377
Drug: ferrous glycine sulfate Tardyferon
RxNorm normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02496377
Drug: ferric carboxymaltose Ferinject
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes